Canopy Growth (CGC) Inventory Average (2017 - 2026)
Canopy Growth (CGC) reported Inventory Average of $78.1 million for Q1 2026, up 18.28% on a YoY basis from $66.1 million in Q1 2025, and up 4.13% sequentially from $75.0 million in Q4 2025.
Canopy Growth (CGC) Inventory Average (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Inventory Average data on file, last reported at $78.1 million in Q1 2026.
- For the quarter ending Q1 2026, Inventory Average rose 18.28% year-over-year to $78.1 million; the trailing twelve-month figure through Mar 2026 stood at $78.1 million (up 18.28% YoY), and the FY2026 full-year result was $78.1 million, up 25.5% from the prior year.
- Inventory Average improved to $78.1 million in Q1 2026, from $75.0 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $225.8 million in Q1 2022 to a low of $59.6 million in Q2 2024.
- A 5-year average of $97.6 million and a median of $75.0 million in 2025 frame the typical range for Inventory Average.
- Across the five-year window, Inventory Average sank 59.67% in 2023 and increased 18.28% in 2026, its largest moves.
- Tracing CGC's Inventory Average over 5 years: stood at $160.0 million in 2022, then plunged by 59.67% to $64.5 million in 2023, then gained by 1.49% to $65.5 million in 2024, then advanced by 14.56% to $75.0 million in 2025, then rose by 4.13% to $78.1 million in 2026.
- Business Quant data shows CGC's Inventory Average at $78.1 million in Q1 2026, $75.0 million in Q4 2025, and $71.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.18 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 9.02 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 180.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.11 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.96 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 66.75 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.73 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 78.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.14 Mn |
| Dec 31, 2025 | 75.04 Mn |
| Sep 30, 2025 | 71.05 Mn |
| Jun 30, 2025 | 67.44 Mn |
| Mar 31, 2025 | 66.06 Mn |
| Dec 31, 2024 | 65.50 Mn |
| Sep 30, 2024 | 63.92 Mn |
| Jun 30, 2024 | 59.58 Mn |
| Mar 31, 2024 | 60.60 Mn |
| Dec 31, 2023 | 64.55 Mn |
| Sep 30, 2023 | 85.50 Mn |
| Jun 30, 2023 | 83.66 Mn |
| Mar 31, 2023 | 109.63 Mn |
| Dec 31, 2022 | 160.02 Mn |
| Sep 30, 2022 | 161.78 Mn |
| Jun 30, 2022 | 161.34 Mn |
| Mar 31, 2022 | 225.82 Mn |
| Dec 31, 2021 | 285.42 Mn |
| Sep 30, 2021 | 307.79 Mn |
| Jun 30, 2021 | 312.82 Mn |